Pharma Focus Asia

Oxford Properties Group Invests US$91 million for GMP Facility in USA


Oxford Properties Group sells state-of-the-art GMP facility in Marlborough,USA for US$91 million to Moderna.


The new state-of-the-art GMP facility occupies 140,000 square feet.

The purpose-built facility is designed for biomanufacturing processes and has been constructed with high-quality specifications for the building. It features two storeys, with a maximum clear height of 36 feet, which allows for efficient manufacturing processes.

The facility also includes four loading docks and multiple freight elevators, indicating that it is equipped to handle the transportation and movement of materials and products effectively. This setup is essential for the smooth operation of a biomanufacturing facility.

Oxford currently possesses a North American cGMP portfolio covering 1.4 million square feet, and they are in the process of expanding with an additional development pipeline of around 600,000 square feet. 

This comprehensive strategy is designed to offer a full spectrum of essential, advanced real estate infrastructure for seamlessly conducting research, development, and manufacturing of groundbreaking future therapeutics.

Scheduled for a late 2024 debut following significant expansion efforts, the facility is poised to create more than 200 employment opportunities by 2026.


Name      Oxford Properties Group
Type        New Construction
Budget    US$91 million
Year        2026

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference